

Michael Witcher

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9640651/michael-witcher-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

29
papers

963
citations

18
h-index

31
g-index

32
ext. papers

1,314
ext. citations

10.2
avg, IF

4.49
L-index

#	Paper	IF	Citations
29	POGZ promotes homology-directed DNA repair in an HP1-dependent manner. <i>EMBO Reports</i> , 2021 , e51044	6.4	0
28	Achieving clinical success with BET inhibitors as anti-cancer agents. <i>British Journal of Cancer</i> , 2021 , 124, 1478-1490	8.7	40
27	Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles. <i>Blood Advances</i> , 2021 , 5, 1682-1694	7.8	13
26	STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer. <i>Nature Communications</i> , 2021 , 12, 3299	17.4	5
25	Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 64-75	6.1	3
24	Methionine Metabolism Shapes T Helper Cell Responses through Regulation of Epigenetic Reprogramming. <i>Cell Metabolism</i> , 2020 , 31, 250-266.e9	24.6	91
23	Small-Cell Carcinoma of the Ovary, Hypercalcemic Type-Genetics, New Treatment Targets, and Current Management Guidelines. <i>Clinical Cancer Research</i> , 2020 , 26, 3908-3917	12.9	28
22	CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. <i>Nature Communications</i> , 2019 , 10, 558	17.4	42
21	Beyond EZH2: is the polycomb protein CBX2 an emerging target for anti-cancer therapy?. <i>Expert Opinion on Therapeutic Targets</i> , 2019 , 23, 565-578	6.4	14
20	SWI/SNF-Compromised Cancers Are Susceptible to Bromodomain Inhibitors. <i>Cancer Research</i> , 2019 , 79, 2761-2774	10.1	36
19	Oncogenic activity of poly (ADP-ribose) glycohydrolase. <i>Oncogene</i> , 2019 , 38, 2177-2191	9.2	15
18	MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma. <i>Cancer Research</i> , 2019 , 79, 1646-1657	10.1	19
17	HIV-1 Employs Multiple Mechanisms To Resist Cas9/Single Guide RNA Targeting the Viral Primer Binding Site. <i>Journal of Virology</i> , 2018 , 92,	6.6	20
16	Peroxisomes and cancer: The role of a metabolic specialist in a disease of aberrant metabolism. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2018 , 1870, 103-121	11.2	32
15	CTCF facilitates DNA double-strand break repair by enhancing homologous recombination repair. <i>Science Advances</i> , 2017 , 3, e1601898	14.3	34
14	Competition between translation initiation factor eIF5 and its mimic protein 5MP determines non-AUG initiation rate genome-wide. <i>Nucleic Acids Research</i> , 2017 , 45, 11941-11953	20.1	36
13	Insights into a novel nuclear function for Fascin in the regulation of the amino-acid transporter SLC3A2. <i>Scientific Reports</i> , 2016 , 6, 36699	4.9	14

12	Epigenetic silencing of tumor suppressor genes: Paradigms, puzzles, and potential. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016 , 1865, 275-88	11.2	87
11	Haploinsufficiency of the ESCRT Component HD-PTP Predisposes to Cancer. <i>Cell Reports</i> , 2016 , 15, 1893-900	11.2	25
10	Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors. <i>BMC Medicine</i> , 2015 , 13, 217	11.4	14
9	Anticancer Properties of Phyllanthus emblica (Indian Gooseberry). <i>Oxidative Medicine and Cellular Longevity</i> , 2015 , 2015, 950890	6.7	34
8	Analysis of changes to mRNA levels and CTCF occupancy upon TFII-I knockdown. <i>Genomics Data</i> , 2015 , 4, 17-21		3
7	Genome-wide targeting of the epigenetic regulatory protein CTCF to gene promoters by the transcription factor TFII-I. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, E677-86	11.5	50
6	Gallotannin imposes S phase arrest in breast cancer cells and suppresses the growth of triple-negative tumors in vivo. <i>PLoS ONE</i> , 2014 , 9, e92853	3.7	19
5	Functional and molecular characterization of the role of CTCF in human embryonic stem cell biology. <i>PLoS ONE</i> , 2012 , 7, e42424	3.7	16
4	Epigenetic silencing of the p16(INK4a) tumor suppressor is associated with loss of CTCF binding and a chromatin boundary. <i>Molecular Cell</i> , 2009 , 34, 271-84	17.6	178
3	Retinoic acid modulates chromatin to potentiate tumor necrosis factor alpha signaling on the DIF2 promoter. <i>Nucleic Acids Research</i> , 2008 , 36, 435-43	20.1	12
2	Combination of retinoic acid and tumor necrosis factor overcomes the maturation block in a variety of retinoic acid-resistant acute promyelocytic leukemia cells. <i>Blood</i> , 2004 , 104, 3335-42	2.2	22
1	Synergy between all-trans retinoic acid and tumor necrosis factor pathways in acute leukemia cells. <i>Blood</i> , 2003 , 102, 237-45	2.2	61